Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation
Authors
Keywords
-
Journal
Nature Communications
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-02-23
DOI
10.1038/s41467-021-21445-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CAR T cells: continuation in a revolution of immunotherapy
- (2020) Anurag K Singh et al. LANCET ONCOLOGY
- Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T cell dysfunction
- (2020) Nathan Singh et al. Cancer Discovery
- Driving CAR T cell translation forward
- (2019) Liora Schultz et al. Science Translational Medicine
- Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
- (2019) Mohamed-Reda Benmebarek et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Bispecific antibodies: a mechanistic review of the pipeline
- (2019) Aran F. Labrijn et al. NATURE REVIEWS DRUG DISCOVERY
- Engineering strategies to overcome the current roadblocks in CAR T cell therapy
- (2019) Sarwish Rafiq et al. Nature Reviews Clinical Oncology
- Bispecific antibodies in cancer immunotherapy
- (2019) Christoph Rader CURRENT OPINION IN BIOTECHNOLOGY
- Bispecific antibody based therapeutics: Strengths and challenges
- (2018) Archana Thakur et al. BLOOD REVIEWS
- A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity
- (2018) Norman Sachs et al. CELL
- Interleukin-10 Directly Inhibits CD8 + T Cell Function by Enhancing N-Glycan Branching to Decrease Antigen Sensitivity
- (2018) Logan K. Smith et al. IMMUNITY
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity
- (2018) A. J. Davenport et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity
- (2018) Elise Alspach et al. Cold Spring Harbor Perspectives in Biology
- CARs versus BiTEs: A Comparison between T Cell–Redirection Strategies for Cancer Treatment
- (2018) Clare Y. Slaney et al. Cancer Discovery
- Redirected T Cell Cytotoxicity in Cancer Therapy
- (2018) Raphael A. Clynes et al. Annual Review of Medicine
- FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma
- (2018) Najat Bouchkouj et al. CLINICAL CANCER RESEARCH
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- p95HER2–T cell bispecific antibody for breast cancer treatment
- (2018) Irene Rius Ruiz et al. Science Translational Medicine
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
- (2017) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Molecular Signatures Database Hallmark Gene Set Collection
- (2015) Arthur Liberzon et al. Cell Systems
- ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
- (2014) Carlos L. Arteaga et al. CANCER CELL
- It’s the Peptide-MHC Affinity, Stupid
- (2013) Thomas Kammertoens et al. CANCER CELL
- Histone modifications at human enhancers reflect global cell-type-specific gene expression
- (2009) Nathaniel D. Heintzman et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started